Psilocybin Therapy for Anxiety

The honest framing of psilocybin therapy for anxiety: the strongest published evidence is in cancer-related anxiety, not in primary anxiety disorders. The two foundational randomized trials — Griffiths 2016 and Ross 2016 — were conducted in patients with life-threatening cancer who had clinically significant anxiety and depression, and showed sustained reductions in both. Agin-Liebes 2020 followed the Ross cohort 4–5 years later and found durable response in many participants. Outside the cancer-related context, psilocybin's evidence in primary generalized anxiety disorder, social anxiety disorder, or panic disorder is preliminary at best — there are no large RCTs in primary anxiety analogous to Bogenschutz's AUD trial or Goodwin's TRD trial. By contrast, ketamine has a more developed primary-anxiety evidence base (the Glue group's GAD/SAD trials and the Whittaker 2021 meta-analysis showing OR 28.94 for SAD). For Canadian patients pursuing psilocybin SAP for anxiety specifically, the most defensible cases are cancer-related anxiety in palliative-care contexts (where evidence and SAP foundation indication align). This article walks through the evidence honestly, without overstating either direction.

Key takeaways

• The primary published psilocybin anxiety evidence is in cancer-related anxiety: Griffiths 2016 (Johns Hopkins, N=51), Ross 2016 (NYU, N=29), Agin-Liebes 2020 long-term follow-up.
• Non-cancer primary anxiety evidence is preliminary — no large RCTs in primary GAD (generalized anxiety disorder), SAD (social anxiety disorder), or panic disorder analogous to the cancer-related trials or to ketamine's anxiety RCT base.
• For the cancer-anxiety overlap, this article connects to Psilocybin Therapy for End-of-Life Distress, which covers the same evidence in the palliative-care framing.
• Ketamine has a more developed primary-anxiety evidence base — the Glue 2017/2018/2020 GAD/SAD trials and Whittaker 2021 meta-analysis (pooled SAD OR 28.94). For ketamine context, see Ketamine Therapy for Anxiety.
• SAP applications for anxiety alone are less common than for end-of-life distress or TRD. Most Canadian SAP-approved anxiety cases sit within cancer-related or comorbid TRD frames.
• Mechanism is plausible for primary anxiety circuits (5-HT2A modulation, DMN deactivation, amygdala-PFC reorganization) but mechanism is not the same as evidence.

What does the evidence actually show?

Cancer-related anxiety — the strongest evidence

Most published psilocybin anxiety evidence is in cancer-related psychiatric distress, where anxiety frequently co-occurs with depression and demoralization in patients facing terminal or serious illness.

Griffiths et al. 2016, J Psychopharmacology — Johns Hopkins double-blind RCT (N=51) in patients with life-threatening cancer and clinically significant depression or anxiety. A single high-dose psilocybin session (22 or 30 mg per 70 kg) produced substantial decreases in both depression and anxiety sustained at 6-month follow-up; ~80% of high-dose participants maintained response.

Ross et al. 2016, J Psychopharmacology — NYU companion RCT (N=29) in cancer-related anxiety and depression. Single 0.3 mg/kg psilocybin produced rapid and sustained antidepressant and anxiolytic effects with 60–80% response at 6.5 months.

Agin-Liebes et al. 2020, J Psychopharmacology — long-term follow-up of the Ross cohort. 60–80% of surviving participants maintained response 4–5 years post-treatment, including the anxiety dimension.

For the cancer-related framing specifically, see Psilocybin Therapy for End-of-Life Distress — this article covers the same evidence in the palliative-care context.

Primary anxiety disorders — preliminary

For primary anxiety disorders without cancer-related context (generalized anxiety disorder, social anxiety disorder, panic disorder), the published psilocybin evidence is much smaller. There are no large RCTs in primary anxiety analogous to:

• The Bogenschutz 2022 AUD trial (N=95) within psilocybin medicine
• The Goodwin 2022 TRD trial (N=233) within psilocybin medicine
• The Glue 2017/2018/2020 GAD/SAD trials and Whittaker 2021 meta-analysis (pooled SAD OR 28.94) within ketamine medicine

Most psilocybin primary-anxiety data exists as secondary outcomes within depression-focused trials (Carhart-Harris 2016, Davis 2021, Goodwin 2022, Carhart-Harris 2021 NEJM) where anxiety scores improved alongside depression scores — consistent with the high anxious-depression comorbidity in TRD populations.

Anecdotally and through case reports, psilocybin SAP-pathway clinicians have reported anxiolytic effects in patients with primary anxiety, but this does not constitute the evidence base needed to position psilocybin as established therapy for primary anxiety disorders.

Mechanism applicable to anxiety circuits

The mechanistic story applies to anxiety circuits as it does to depression:

• 5-HT2A serotonin receptor agonism triggers the cascade leading to neuroplasticity and synaptogenesis.
• Default mode network modulation (Carhart-Harris 2012) — DMN deactivation may reduce the rumination loops that maintain anxiety.
• Amygdala-prefrontal cortex circuit reorganization — research on psychedelic effects on threat processing and fear extinction is active. The mechanism is plausible but not fully characterized for anxiety specifically.
• Mystical-type experience (Roseman 2018) — subjective experience quality predicts outcomes in TRD; whether the same mediator applies to primary anxiety is less established.

The honest framing: mechanism is plausible for anxiety circuits, but mechanism is not the same as evidence. Patients evaluating psilocybin for primary anxiety should weigh the smaller evidence base honestly.

Where psilocybin sits in the anxiety treatment landscape

CANMAT 2014 anxiety guidelines (and subsequent updates) recommend SSRIs/SNRIs and CBT as first-line for GAD, SAD, panic disorder. Augmentation strategies, benzodiazepines (short-term), and other pharmacotherapies follow.

Psilocybin is not in the CANMAT anxiety guidelines. SAP applications for anxiety alone are less common than for end-of-life distress (where the evidence is strongest) or TRD (where evidence is also stronger and more replicated).

Ketamine has a more developed primary-anxiety evidence base than psilocybin. The Glue 2017 J Psychopharmacology RCT in treatment-refractory GAD/SAD (N=12, 83% response at 0.5–1 mg/kg subcutaneous), Glue 2018 maintenance RCT, Glue 2020 double-blind active-controlled replication, Taylor 2018 Yale SAD RCT, and Whittaker 2021 meta-analysis with pooled SAD OR 28.94 — together represent meaningfully more rigorous primary-anxiety RCT evidence than the parallel psilocybin literature.

For the ketamine primary-anxiety detail, see Ketamine Therapy for Anxiety.

How the SAP pathway works for anxiety-related applications

For Canadian SAP applications involving anxiety, the most defensible cases are:

1. Cancer-related anxiety in patients with life-threatening illness — the foundational SAP indication, supported by Griffiths 2016 and Ross 2016. Often framed as end-of-life distress with anxiety as the predominant component.
2. Comorbid TRD with anxious features — anxious depression where the depression component drives the SAP application but the anxiety component is part of the clinical picture.
3. Anxious depression in palliative-care or oncology contexts — overlap with the cancer-anxiety evidence.

Less defensible (and less commonly approved) SAP cases:

• Primary GAD without comorbid serious illness, where evidence is preliminary and conventional treatment options (SSRIs, SNRIs, CBT) are well-established.
• Primary social anxiety disorder without comorbid serious illness, where ketamine has more substantial evidence and is more accessible.
• Primary panic disorder, where evidence is minimal.

For patients with primary anxiety disorders who have not adequately tried first-line treatments (SSRIs/SNRIs, CBT), conventional pharmacotherapy and psychotherapy remain the appropriate next steps. The ATMA CENA intake call screens for fit and is honest about evidence boundaries.

How ATMA CENA supports SAP-pathway anxiety patients

For patients pursuing psilocybin SAP for anxiety-related indications, ATMA CENA's role is the same as across the cluster:

• The medical SAP application is initiated by the patient's prescribing physician or psychiatric consultant — not ATMA CENA directly.
• ATMA CENA supports preparation and integration through the three-phase psychedelic-assisted therapy model.
• The coordinated care model lets the patient's existing treating clinician remain primary while ATMA CENA's clinical infrastructure provides the psychotherapy wraparound.
• ATMA CENA's intake call screens honestly for evidence-fit; some patients pursuing psilocybin for primary anxiety may benefit more from ketamine therapy or established anxiety treatment given the asymmetric evidence base.

Frequently asked questions

Is psilocybin approved for anxiety in Canada? No — psilocybin has no Health Canada-approved indication. Canadian access for anxiety is via SAP only, and the strongest evidence is in cancer-related anxiety rather than primary anxiety disorders.

What's the strongest evidence for psilocybin in anxiety? The Griffiths 2016 and Ross 2016 cancer trials, both published in J Psychopharmacology, plus the Agin-Liebes 2020 long-term follow-up. All three are in cancer-related anxiety/depression, not primary anxiety disorders.

Is psilocybin good for generalized anxiety disorder? The published evidence is preliminary. There is no large RCT in primary GAD analogous to the cancer-related trials. Some patients pursuing SAP for psilocybin have anxious depression with GAD features, but psilocybin is not established for primary GAD as a first-line consideration.

What about social anxiety disorder? Ketamine has a more developed SAD evidence base — the Glue 2017/2018/2020 trials, Taylor 2018 Yale RCT, and Whittaker 2021 meta-analysis with pooled SAD OR 28.94 outperform the published psilocybin SAD evidence. For SAD specifically, ketamine is more evidence-supported.

Should I consider ketamine instead for primary anxiety? Often yes, if access and coverage support it. Ketamine has a more developed primary-anxiety evidence base, broader Canadian access (off-label), and more widely available coverage pathways. See Ketamine Therapy for Anxiety and Psilocybin vs Ketamine Therapy.

What about cancer-related anxiety? This is the strongest psilocybin anxiety indication. See Psilocybin Therapy for End-of-Life Distress, which covers the same evidence in the palliative-care framing where the anxiety component is documented and SAP foundation indication aligns.

Can I do psilocybin therapy if I'm on an SSRI for anxiety? This is a clinical decision with the prescribing physician. Many published psilocybin trials tapered SSRIs before dosing under supervision (theoretical serotonin syndrome at high doses; possible blunting of psychedelic effect). Some clinical models continue lower-dose SSRI through dosing. Discuss with your psychiatrist and ATMA CENA intake.

What about benzodiazepines? Benzodiazepines may attenuate psilocybin's psychoactive effect (similar to the documented attenuation of ketamine's antidepressant effect by high-dose benzos). Many trial protocols hold benzodiazepines on dosing day. Discuss with your prescriber.

What's the SAP approval rate for anxiety applications? SAP authorizations for anxiety alone are less common than for end-of-life distress or TRD. Most Canadian SAP-approved anxiety cases sit within cancer-related or comorbid TRD frames. Approval depends on documentation, comorbidity, and a willing prescribing physician.

Where can I access psilocybin anxiety therapy in Canada? SAP-authorized clinicians. For cancer-related anxiety, palliative-care psychiatry providers and clinics with SAP-pathway experience (Roots to Thrive Nanaimo, Quebec collective via Drs. Farzin/Stephan, TheraPsil-trained clinicians) are the established pathways. For primary anxiety, evaluation of fit and alternatives (including ketamine) is part of intake.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
3. Ross S, et al. (2016). Psilocybin in cancer-related anxiety/depression. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909165/
4. Agin-Liebes GI, et al. (2020). Long-term follow-up of psilocybin-assisted therapy in cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/31916890/
5. Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state — DMN. PNAS. https://pubmed.ncbi.nlm.nih.gov/22308440/
6. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute psychedelic experience predicts therapeutic efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
7. Glue P, et al. (2017). Ketamine for treatment-refractory GAD/SAD — comparison context. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/28441895/
8. Whittaker E, et al. (2021). Meta-analysis of ketamine for refractory anxiety spectrum disorders — comparison context. Ther Adv Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/34925757/
9. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles in this cluster

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• How to Access Psilocybin Therapy in Canada (SAP)
• Psilocybin Therapy for End-of-Life Distress
• Psilocybin Therapy for Treatment-Resistant Depression
• Psilocybin vs Ketamine Therapy
• Ketamine Therapy for Anxiety — ketamine anxiety evidence and access
• Find care near you

Last updated: 2026-05-06